Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Real-time Estimate Cboe Europe  -  08:29 2022-09-29 am EDT
38.20 CHF   -0.26%
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug
MT
09/21Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BASILEA PHARMACEUTICA AG
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital
MT
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
GL
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
DJ
09/20Basilea Pharmaceutica Boosts FY22 Revenue Outlook After Disposal Deal For Oncology Asse..
MT
09/20Basilea Pharmaceutica Sells Oncology Asset Rights To South Korea's SillaJen
MT
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
GL
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
DJ
09/20Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022
CI
09/20Basilea Pharmaceutica AG Enters into Asset Purchase Agreement and Sub-License Agreement..
CI
09/08Basilea to Sell Preclinical Oncology Program to Nodus Oncology in $248 Million Deal
MT
09/08Basilea announces sale of preclinical oncology program to Nodus Oncology
GL
09/08Basilea announces sale of preclinical oncology program to Nodus Oncology
DJ
09/07Basilea Secures $76 Million Senior Secured Loan to Refinance Bonds Due December
MT
09/07Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-di..
GL
More most relevant news
All news about BASILEA PHARMACEUTICA AG
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug
MT
09/21Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital
MT
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
GL
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
DJ
09/20Basilea Pharmaceutica Boosts FY22 Revenue Outlook After Disposal Deal For Oncology Asse..
MT
09/20Basilea Pharmaceutica Sells Oncology Asset Rights To South Korea's SillaJen
MT
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
GL
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
DJ
09/20Basilea Pharmaceutica AG Enters into Asset Purchase Agreement and Sub-License Agreement..
CI
More news
News in other languages on BASILEA PHARMACEUTICA AG
09/21Basilea va utiliser un prêt pour rembourser un emprunt convertible
09/21Basilea meldet Vollzug des Athyrium-Darlehens von 75 Millionen Franken
09/21Basilea Pharmaceutica obtient un prêt garanti de premier rang de 78 millions de dollars..
09/21Basilea gibt Vollzug (Closing) der Vereinbarung mit Athyrium über vorrangig besichertes..
09/20Basilea verkauft Krebs-Kandidaten und erhöht Ausblick 2022
09/20Basilea poursuit son désengagement de l'oncologie, modère son déficit pour 2022
09/20Basilea Pharmaceutica revoit à la hausse ses prévisions de revenus pour l'exercice 22 a..
09/20Basilea Pharmaceutica vend les droits sur les actifs oncologiques à la société sud-coré..
09/20Basilea gibt Verkauf der Rechte an Onkologie-Wirkstoff BAL0891 an SillaJen bekannt und ..
09/20Basilea Pharmaceutica AG conclut un accord d'achat d'actifs et un accord de sous-licenc..
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
2021Basilea Pharmaceutica : Edison Investment Research Lowers Price Ta..
MT
More recommendations
Press releases
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
GL
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
GL
09/08Basilea announces sale of preclinical oncology program to Nodus Oncology
GL
09/07Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-di..
GL
More press releases
Upcoming event on BASILEA PHARMACEUTICA AG